European Leukemia Trial Registry
Trial: AMLSG 10-07

More Details
Title SU11248 Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML
Scientific Title Phase I/II Clinical Study of SU11248 (Sutent) Combined With Standard Chemotherapy With Cytosine Arabinoside and Daunorubicin in Patients With FLT3 Mutated AML Over 60 Years of Age
Short Title AMLSG 10-07
Trialgroup AMLSG Ulm
Type of Trial single-group, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 60 years
Status No longer recruiting
Start of Recruitment 30.11.2008
Leader Fiedler, Prof. Dr. med., Walter
Contactperson

Study Centre
Groner, Silja
Tel: +49 (0)731 500-45911
Fax: +49 (0)731 500-45915
Email: silja.groner@uniklinik-ulm.de

Centre of Trial Universitätsklinikum Hamburg-Eppendorf
Shortprotocol Shortprotocol
Diagnostics

Cytogenetics
Labor für Zytogenetische und Molekulargenetische Diagnostik, Klinik für Innere Med. III, Universitätsklinikum Ulm
Labor für Leukämieforschung der Medizinischen Hochschule Hannover

created 23.01.2009 Roswitha Kotthoff
changed 13.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org